{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_2551"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_2551","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Elucidation of the mechanisms of interaction between bile acids and the interleukin-23/interleukin-17 axis during cholestasis","abstract":"Cholestatic liver disease occurs when bile flow is disrupted, intrahepatically and/or extrahepatically, leading to neutrophil accumulation and elevated bile acid concentrations especially taurine-conjugated bile acids. The robust neutrophilic inflammatory response propagates hepatocellular injury, which is dependent upon macrophage inflammatory protein-2 (MIP-2) expression. Previously, we demonstrated that taurocholic acid (TCA) induces the expression of MIP-2 via ERK activation of early growth response factor-1 (Egr-1) in hepatocytes. However, the mechanisms of bile acid induced neutrophilic inflammation are still not well understood.Interleukin-17A (IL-17A) is a Th17 cytokine that regulates neutrophil recruitment, defense against bacterial infection, and inflammation induced injury in autoimmune diseases. IL-17A expression is increased in patients with primary biliary cirrhosis and murine models of liver disease. Therefore, we hypothesized that IL-17A promotes inflammation in cholestatic liver disease. To test this hypothesis, we performed bile duct ligation (BDL), a murine model of obstructive cholestasis, on mice treated with an anti-IL-17A antibody. The neutralization of IL-17A reduced alanine aminotransferase (ALT) activity and areas of necrosis in mice subjected to BDL. The expression of pro-inflammatory mediators and neutrophil cell count was decreased in anti-IL-17A BDL mice. Furthermore, IL-17A synergistically enhances MIP-2 induction by TCA in hepatocytes. IL-17F, another member of the IL-17 family, did not affect hepatocellular injury or inflammation in BDL mice. However, IL-17F had a similar synergistic interaction with TCA in vitro. These data demonstrate that IL-17A is the predominant Th17 cytokine that contributes to the pathogenesis of cholestasis.To determine the molecular mechanisms that underline this synergistic interaction, we investigated known signaling pathways (i.e. C/EBP&beta;, p38, and JNK) that regulate IL-17A synergistic enhancement of pro-inflammatory mediators by other cytokines. The knockdown of C/EBP&beta; did not reduce IL-17A induction of MIP-2, but the upregulation of MIP-2 mRNA levels was attenuated in TCA treated hepatocytes. However, hepatocellular injury and inflammation was unaffected in C/EBP&beta; heterozygous knockout mice subjected to BDL for 3 days. Both p38 and JNK signaling pathways are activated by bile acids; whereas, treatment with IL-17A inhibited the activation of p38 and JNK. Consistently, inhibition of p38 and JNK signaling further promoted MIP-2 induction by bile acids. These results demonstrate the transcription factor, C/EBP&beta;, as an alternative pathway by which bile acid regulate the inflammatory response in hepatocytes. Furthermore, these data suggest that IL-17A inhibition of p38 and JNK signaling promotes the synergistic enhancement of MIP-2 induction by bile acids. Interleukin-23 (IL-23) is critical for Th17 cellular expansion and secretion of IL-17A. Mice subjected to BDL had a biphasic induction of IL-23 mRNA levels similar to TCA serum concentrations. Therefore, we tested the hypothesis that bile acids regulate hepatic IL-23 expression. IL-23 protein expression was increased in mice fed a 0.3% cholic acid diet. Furthermore, IL-23 protein and mRNA levels were elevated in hepatocytes treated with TCA via a JNK- and AKT-dependent manner. These data suggest that pathophysiological concentrations of bile acids promote a positive feedback loop in the IL-23/IL-17A axis during cholestasis.Overall, these studies demonstrate the molecular mechanisms underlying bile acid induction of the hepatic Th17 inflammatory response in cholestatic liver disease.","abstract_html":"Cholestatic liver disease occurs when bile flow is disrupted, intrahepatically and/or extrahepatically, leading to neutrophil accumulation and elevated bile acid concentrations especially taurine-conjugated bile acids. The robust neutrophilic inflammatory response propagates hepatocellular injury, which is dependent upon macrophage inflammatory protein-2 (MIP-2) expression. Previously, we demonstrated that taurocholic acid (TCA) induces the expression of MIP-2 via ERK activation of early growth response factor-1 (Egr-1) in hepatocytes. However, the mechanisms of bile acid induced neutrophilic inflammation are still not well understood.Interleukin-17A (IL-17A) is a Th17 cytokine that regulates neutrophil recruitment, defense against bacterial infection, and inflammation induced injury in autoimmune diseases. IL-17A expression is increased in patients with primary biliary cirrhosis and murine models of liver disease. Therefore, we hypothesized that IL-17A promotes inflammation in cholestatic liver disease. To test this hypothesis, we performed bile duct ligation (BDL), a murine model of obstructive cholestasis, on mice treated with an anti-IL-17A antibody. The neutralization of IL-17A reduced alanine aminotransferase (ALT) activity and areas of necrosis in mice subjected to BDL. The expression of pro-inflammatory mediators and neutrophil cell count was decreased in anti-IL-17A BDL mice. Furthermore, IL-17A synergistically enhances MIP-2 induction by TCA in hepatocytes. IL-17F, another member of the IL-17 family, did not affect hepatocellular injury or inflammation in BDL mice. However, IL-17F had a similar synergistic interaction with TCA in vitro. These data demonstrate that IL-17A is the predominant Th17 cytokine that contributes to the pathogenesis of cholestasis.To determine the molecular mechanisms that underline this synergistic interaction, we investigated known signaling pathways (i.e. C/EBP&amp;beta;, p38, and JNK) that regulate IL-17A synergistic enhancement of pro-inflammatory mediators by other cytokines. The knockdown of C/EBP&amp;beta; did not reduce IL-17A induction of MIP-2, but the upregulation of MIP-2 mRNA levels was attenuated in TCA treated hepatocytes. However, hepatocellular injury and inflammation was unaffected in C/EBP&amp;beta; heterozygous knockout mice subjected to BDL for 3 days. Both p38 and JNK signaling pathways are activated by bile acids; whereas, treatment with IL-17A inhibited the activation of p38 and JNK. Consistently, inhibition of p38 and JNK signaling further promoted MIP-2 induction by bile acids. These results demonstrate the transcription factor, C/EBP&amp;beta;, as an alternative pathway by which bile acid regulate the inflammatory response in hepatocytes. Furthermore, these data suggest that IL-17A inhibition of p38 and JNK signaling promotes the synergistic enhancement of MIP-2 induction by bile acids. Interleukin-23 (IL-23) is critical for Th17 cellular expansion and secretion of IL-17A. Mice subjected to BDL had a biphasic induction of IL-23 mRNA levels similar to TCA serum concentrations. Therefore, we tested the hypothesis that bile acids regulate hepatic IL-23 expression. IL-23 protein expression was increased in mice fed a 0.3% cholic acid diet. Furthermore, IL-23 protein and mRNA levels were elevated in hepatocytes treated with TCA via a JNK- and AKT-dependent manner. These data suggest that pathophysiological concentrations of bile acids promote a positive feedback loop in the IL-23/IL-17A axis during cholestasis.Overall, these studies demonstrate the molecular mechanisms underlying bile acid induction of the hepatic Th17 inflammatory response in cholestatic liver disease.","abstract_has_math":false,"creators":["O'Brien, Kate Maureen"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Copple, Bryan L.","Dorrance, Anne","Luyendyk, James P.","Roth, Robert"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014","date_published":"2014","updated_at":"2026-11-18T17:46:21Z","subjects":["Bile acids","Gastroenterology","Inflammation","Interleukins","Liver--Diseases"],"languages":["English"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:2551","isbn:9781303716904","isbn:1303716909","oclc:931761108","umi:3611182","local:OBrien_grad.msu_0128D_12681"],"render_values":[{"text":"etd:2551","href":null,"code":true},{"text":"isbn:9781303716904","href":null,"code":true},{"text":"isbn:1303716909","href":null,"code":true},{"text":"oclc:931761108","href":null,"code":true},{"text":"umi:3611182","href":null,"code":true},{"text":"local:OBrien_grad.msu_0128D_12681","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/wg84-2y62","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/wg84-2y62","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_2551","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Copple, Bryan L.","Dorrance, Anne","Luyendyk, James P.","Roth, Robert"]},{"key":"dc:creator","label":"Author","values":["O'Brien, Kate Maureen"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2014"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["Text","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Bile acids","Gastroenterology","Inflammation","Interleukins","Liver--Diseases"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:2551","isbn:9781303716904","isbn:1303716909","oclc:931761108","umi:3611182","local:OBrien_grad.msu_0128D_12681","https://doi.org/doi:10.25335/wg84-2y62"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Cholestatic liver disease occurs when bile flow is disrupted, intrahepatically and/or extrahepatically, leading to neutrophil accumulation and elevated bile acid concentrations especially taurine-conjugated bile acids. The robust neutrophilic inflammatory response propagates hepatocellular injury, which is dependent upon macrophage inflammatory protein-2 (MIP-2) expression. Previously, we demonstrated that taurocholic acid (TCA) induces the expression of MIP-2 via ERK activation of early growth response factor-1 (Egr-1) in hepatocytes. However, the mechanisms of bile acid induced neutrophilic inflammation are still not well understood.Interleukin-17A (IL-17A) is a Th17 cytokine that regulates neutrophil recruitment, defense against bacterial infection, and inflammation induced injury in autoimmune diseases. IL-17A expression is increased in patients with primary biliary cirrhosis and murine models of liver disease. Therefore, we hypothesized that IL-17A promotes inflammation in cholestatic liver disease. To test this hypothesis, we performed bile duct ligation (BDL), a murine model of obstructive cholestasis, on mice treated with an anti-IL-17A antibody. The neutralization of IL-17A reduced alanine aminotransferase (ALT) activity and areas of necrosis in mice subjected to BDL. The expression of pro-inflammatory mediators and neutrophil cell count was decreased in anti-IL-17A BDL mice. Furthermore, IL-17A synergistically enhances MIP-2 induction by TCA in hepatocytes. IL-17F, another member of the IL-17 family, did not affect hepatocellular injury or inflammation in BDL mice. However, IL-17F had a similar synergistic interaction with TCA in vitro. These data demonstrate that IL-17A is the predominant Th17 cytokine that contributes to the pathogenesis of cholestasis.To determine the molecular mechanisms that underline this synergistic interaction, we investigated known signaling pathways (i.e. C/EBP&beta;, p38, and JNK) that regulate IL-17A synergistic enhancement of pro-inflammatory mediators by other cytokines. The knockdown of C/EBP&beta; did not reduce IL-17A induction of MIP-2, but the upregulation of MIP-2 mRNA levels was attenuated in TCA treated hepatocytes. However, hepatocellular injury and inflammation was unaffected in C/EBP&beta; heterozygous knockout mice subjected to BDL for 3 days. Both p38 and JNK signaling pathways are activated by bile acids; whereas, treatment with IL-17A inhibited the activation of p38 and JNK. Consistently, inhibition of p38 and JNK signaling further promoted MIP-2 induction by bile acids. These results demonstrate the transcription factor, C/EBP&beta;, as an alternative pathway by which bile acid regulate the inflammatory response in hepatocytes. Furthermore, these data suggest that IL-17A inhibition of p38 and JNK signaling promotes the synergistic enhancement of MIP-2 induction by bile acids. Interleukin-23 (IL-23) is critical for Th17 cellular expansion and secretion of IL-17A. Mice subjected to BDL had a biphasic induction of IL-23 mRNA levels similar to TCA serum concentrations. Therefore, we tested the hypothesis that bile acids regulate hepatic IL-23 expression. IL-23 protein expression was increased in mice fed a 0.3% cholic acid diet. Furthermore, IL-23 protein and mRNA levels were elevated in hepatocytes treated with TCA via a JNK- and AKT-dependent manner. These data suggest that pathophysiological concentrations of bile acids promote a positive feedback loop in the IL-23/IL-17A axis during cholestasis.Overall, these studies demonstrate the molecular mechanisms underlying bile acid induction of the hepatic Th17 inflammatory response in cholestatic liver disease.","Thesis (Ph. D.)--Michigan State University. Pharmacology and Toxicology-Environmental Toxicology, 2014","Includes bibliographical references (pages 145-161)"]},{"key":"dc:format","label":"Dc Format","values":["161 pages","application/pdf"]},{"key":"dc:title","label":"Title","values":["Elucidation of the mechanisms of interaction between bile acids and the interleukin-23/interleukin-17 axis during cholestasis"]}]}],"canonical_facts":{"dc:contributor":["Copple, Bryan L.","Dorrance, Anne","Luyendyk, James P.","Roth, Robert"],"dc:creator":["O'Brien, Kate Maureen"],"dc:date":["2014"],"dc:description":["Cholestatic liver disease occurs when bile flow is disrupted, intrahepatically and/or extrahepatically, leading to neutrophil accumulation and elevated bile acid concentrations especially taurine-conjugated bile acids. The robust neutrophilic inflammatory response propagates hepatocellular injury, which is dependent upon macrophage inflammatory protein-2 (MIP-2) expression. Previously, we demonstrated that taurocholic acid (TCA) induces the expression of MIP-2 via ERK activation of early growth response factor-1 (Egr-1) in hepatocytes. However, the mechanisms of bile acid induced neutrophilic inflammation are still not well understood.Interleukin-17A (IL-17A) is a Th17 cytokine that regulates neutrophil recruitment, defense against bacterial infection, and inflammation induced injury in autoimmune diseases. IL-17A expression is increased in patients with primary biliary cirrhosis and murine models of liver disease. Therefore, we hypothesized that IL-17A promotes inflammation in cholestatic liver disease. To test this hypothesis, we performed bile duct ligation (BDL), a murine model of obstructive cholestasis, on mice treated with an anti-IL-17A antibody. The neutralization of IL-17A reduced alanine aminotransferase (ALT) activity and areas of necrosis in mice subjected to BDL. The expression of pro-inflammatory mediators and neutrophil cell count was decreased in anti-IL-17A BDL mice. Furthermore, IL-17A synergistically enhances MIP-2 induction by TCA in hepatocytes. IL-17F, another member of the IL-17 family, did not affect hepatocellular injury or inflammation in BDL mice. However, IL-17F had a similar synergistic interaction with TCA in vitro. These data demonstrate that IL-17A is the predominant Th17 cytokine that contributes to the pathogenesis of cholestasis.To determine the molecular mechanisms that underline this synergistic interaction, we investigated known signaling pathways (i.e. C/EBP&beta;, p38, and JNK) that regulate IL-17A synergistic enhancement of pro-inflammatory mediators by other cytokines. The knockdown of C/EBP&beta; did not reduce IL-17A induction of MIP-2, but the upregulation of MIP-2 mRNA levels was attenuated in TCA treated hepatocytes. However, hepatocellular injury and inflammation was unaffected in C/EBP&beta; heterozygous knockout mice subjected to BDL for 3 days. Both p38 and JNK signaling pathways are activated by bile acids; whereas, treatment with IL-17A inhibited the activation of p38 and JNK. Consistently, inhibition of p38 and JNK signaling further promoted MIP-2 induction by bile acids. These results demonstrate the transcription factor, C/EBP&beta;, as an alternative pathway by which bile acid regulate the inflammatory response in hepatocytes. Furthermore, these data suggest that IL-17A inhibition of p38 and JNK signaling promotes the synergistic enhancement of MIP-2 induction by bile acids. Interleukin-23 (IL-23) is critical for Th17 cellular expansion and secretion of IL-17A. Mice subjected to BDL had a biphasic induction of IL-23 mRNA levels similar to TCA serum concentrations. Therefore, we tested the hypothesis that bile acids regulate hepatic IL-23 expression. IL-23 protein expression was increased in mice fed a 0.3% cholic acid diet. Furthermore, IL-23 protein and mRNA levels were elevated in hepatocytes treated with TCA via a JNK- and AKT-dependent manner. These data suggest that pathophysiological concentrations of bile acids promote a positive feedback loop in the IL-23/IL-17A axis during cholestasis.Overall, these studies demonstrate the molecular mechanisms underlying bile acid induction of the hepatic Th17 inflammatory response in cholestatic liver disease.","Thesis (Ph. D.)--Michigan State University. Pharmacology and Toxicology-Environmental Toxicology, 2014","Includes bibliographical references (pages 145-161)"],"dc:format":["161 pages","application/pdf"],"dc:identifier":["etd:2551","isbn:9781303716904","isbn:1303716909","oclc:931761108","umi:3611182","local:OBrien_grad.msu_0128D_12681","https://doi.org/doi:10.25335/wg84-2y62"],"dc:language":["English"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Bile acids","Gastroenterology","Inflammation","Interleukins","Liver--Diseases"],"dc:title":["Elucidation of the mechanisms of interaction between bile acids and the interleukin-23/interleukin-17 axis during cholestasis"],"dc:type":["Text","Theses"]},"updated_at":"2026-11-18T17:46:21Z"}